Integrated Group Therapy for Bipolar Disorder and Substance Abuse - Weiss, Roger D; Connery, Hilary S
48,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
24 °P sammeln
  • Broschiertes Buch

Packed with practical clinical tools, this book presents an empirically supported treatment expressly designed for clients with both bipolar disorder and substance use disorders. Integrated group therapy teaches essential recovery behaviors and relapse prevention skills that apply to both illnesses. The volume provides a complete session-by-session overview of the approach, including clear guidelines for setting up and running groups, implementing the cognitive-behavioral treatment techniques, and troubleshooting frequently encountered problems. In a large-size format for easy reference and…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Packed with practical clinical tools, this book presents an empirically supported treatment expressly designed for clients with both bipolar disorder and substance use disorders. Integrated group therapy teaches essential recovery behaviors and relapse prevention skills that apply to both illnesses. The volume provides a complete session-by-session overview of the approach, including clear guidelines for setting up and running groups, implementing the cognitive-behavioral treatment techniques, and troubleshooting frequently encountered problems. In a large-size format for easy reference and photocopying, the book features more than 30 reproducible handouts, forms, and bulletin board materials.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Roger D. Weiss, MD, is Professor of Psychiatry at Harvard Medical School and Chief of the Division of Alcohol and Drug Abuse at McLean Hospital in Belmont, Massachusetts. Through his research, international teaching, clinical work, and writings, Dr. Weiss has made significant contributions to the field of substance use disorders, with a particular focus on those individuals with co-occurring psychiatric illness. He has been Principal Investigator on numerous National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism grants, and he recently led a multisite national study of the treatment of prescription opioid dependence as part of the National Institute on Drug Abuse Clinical Trials Network. He has authored over 300 articles and book chapters and has participated in a number of prominent national committees, including serving as vice chair of the American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders. Dr. Weiss is a recipient of the H. David Archibald Award for Outstanding Research and/or Practice in the Addictions from the Centre for Addiction and Mental Health in Toronto. Hilary Smith Connery, MD, PhD, is Clinical Director of the Alcohol and Drug Abuse Treatment Program at McLean Hospital in Belmont, Massachusetts, and Instructor in Psychiatry at Harvard Medical School. Dr. Connery is a clinical researcher who studies innovative behavioral treatments for patients with co-occurring substance use disorders and mental illness. She has special interest in the treatment of patients with opioid dependence and mental illness and has been a recipient of the Eleanor and Miles Shore/Harvard Medical Scholars Fellowship to study this population. She participated as site Principal Investigator on two national studies of buprenorphine treatment of opioid dependence through the National Institute on Drug Abuse Clinical Trials Network, and she is co-investigator on other federally funded clinical research studies addressing substance use treatment in women and medically ill individuals. Dr. Connery also has community psychiatry experience running assertive community treatment teams and studying barriers to recovery among homeless persons. She is currently listed in Best Doctors in America, is a consultant to the Massachusetts Board of Registration in Medicine and the National Football League, and is Area 1 Director for the American Academy of Addiction Psychiatry.